<DOC>
	<DOCNO>NCT01454531</DOCNO>
	<brief_summary>The purpose study assess tolerability AVANZ .</brief_summary>
	<brief_title>An Open Trial Assess Tolerability AVANZ Phleum Pratense Immunotherapy</brief_title>
	<detailed_description>To assess tolerability up-dosing phase AVANZ Phleum pratense . The frequency patient adverse reaction study primary endpoint .</detailed_description>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>History grass pollen rhinoconjunctivitis Positive SPT Phleum pratense Positive specific IgE Phleum pratense Uncontrolled severe asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>